TerrAscend Reports Q4 and Full Year 2025 Financial Results: Key Insights for Investors

Strong Cash Flow, Strategic Market Focus, and Refinanced Debt Highlight 2025 Performance

Key Financial Highlights

• Q4 2025 Net Revenue: \$66.1 million, up 1.6% from Q3 2025.
• Full Year 2025 Net Revenue: \$260.6 million (down 2.8% from 2024).
• Q4 2025 Gross Profit Margin: 52.1% (flat quarter-over-quarter).
• FY 2025 Gross Profit Margin: 52.3% (up from 50.7% in 2024).
• Q4 2025 Net Cash from Operations: \$8.3 million.
• Q4 2025 Free Cash Flow: \$6.6 million (tenth consecutive quarter of positive free cash flow).
• FY 2025 Free Cash Flow: \$25.3 million (down from \$39.4 million in 2024, primarily due to higher tax payments).
• Q4 2025 GAAP Net Loss from Continuing Operations: \$0.5 million (substantial improvement from \$9.9 million loss in Q3 2025).
• FY 2025 GAAP Net Loss from Continuing Operations: \$24.5 million (increased from \$20.9 million in 2024).
• Q4 2025 Adjusted EBITDA: \$16.7 million (25.2% margin, slightly down from Q3).
• FY 2025 Adjusted EBITDA: \$67.8 million (26.0% margin).
• Cash and Cash Equivalents: \$37.4 million at year-end 2025.

Operational and Business Developments

• Core Market Strength: Company highlights robust performance in New Jersey, Maryland, and Pennsylvania, with:
  • New Jersey: Expanded to four dispensaries with the Union Chill acquisition. All three Apothecarium stores ranked in the top 20 statewide out of 260+ stores.
  • Maryland: Operating at a ~\$75 million annual run rate with gross margins near 60%. Two Maryland Apothecarium stores ranked top 10 in the state.
  • Pennsylvania: Both retail and wholesale revenues increased sequentially in Q4. Three Apothecarium stores ranked in the state top 10; Valhalla ranked #3 among edibles and Kind Tree #2 among extracts.
  • Ohio: Entered the market through the acquisition of Ratio Cannabis LLC in Goshen Township.
• Exit from Michigan Market: The company has largely completed the sale of Michigan assets, reporting these as discontinued operations. Proceeds were used to reduce debt and refocus resources on core Northeast markets.
• Exclusive Licensing Agreement: Entered into a partnership with Tyson 2.0 to manufacture and distribute products in Maryland and Pennsylvania, expected to launch immediately.
• Debt Refinancing: Executed a \$79 million non-dilutive refinancing, plus an uncommitted \$35 million term loan facility for potential M&A activities.
• Share Repurchase Program: Renewed a normal course issuer bid, authorizing the repurchase of up to \$10 million USD in common shares through August 2026. In 2025, repurchased 1,117,500 shares at an average price of \$0.44 per share.

Balance Sheet and Capital Structure

• Total Assets: \$557.4 million at December 31, 2025.
• Total Liabilities: \$458.4 million (up from \$430.4 million in 2024).
• Total Shareholders’ Equity: \$99.0 million (down from \$176.8 million in 2024, reflecting losses and discontinued operations).
• Debt Maturities: No material maturities until late 2028, providing financial flexibility.
• Shares Outstanding: ~383 million basic shares, including 309 million common, 11 million preferred (as converted), and 63 million exchangeable shares. 23 million warrants outstanding at a weighted average price of \$4.34 USD.

Key Risks and Considerations for Shareholders

• US Regulatory Environment: Cannabis remains federally illegal in the US. While enforcement trends favor state-legal operators, federal intervention remains a significant risk.
• Continued Losses and Margin Pressure: While operating cash flow and adjusted EBITDA remain positive, the company continues to post net losses, with a net loss from continuing operations of \$24.5 million in 2025.
• Tax Impact: FY 2025 cash flow was affected by \$9.4 million in net tax payments, compared to a \$5 million refund in 2024—a factor in the reduced free cash flow.
• Strategic Focus: Ongoing exit from Michigan reduces exposure to underperforming assets, but also means less geographic diversification in the short term.
• M&A Activity: The company has access to significant undrawn credit for accretive acquisitions but remains selective and disciplined in its approach.

Conference Call Details

Management will discuss these results in a conference call on March 12, 2026, at 5:00 p.m. Eastern Time.
Webcast: https://app.webinar.net/EPJ9wXNjKl1
Dial-in Number: 1-888-510-2154
Replay: 1-289-819-1450 or 1-888-660-6345 (Entry Code: 77201#) until March 26, 2026

Summary and Potential Impact on Share Price

TerrAscend’s Q4 and full year 2025 results demonstrate ongoing strength in its core Northeast markets, consistent positive cash flow generation, improved gross margins, and disciplined capital allocation. The company’s exit from Michigan, successful refinancing, and preparation for further M&A position it for future growth and improved profitability. However, the ongoing net losses, reduced year-over-year revenue, and persistent regulatory risks in the US cannabis sector remain important considerations for investors.

The combination of improved operational metrics, strategic market focus, and capital structure enhancements could positively influence share value, especially if the company continues to deliver margin and cash flow improvements while executing on growth initiatives and maintaining regulatory compliance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult with financial advisors and consider the company’s filings and risk factors before making investment decisions. The cannabis industry remains subject to significant regulatory risk, especially in the United States, and actual results may differ from management’s outlook due to market or regulatory changes.

View TerrAscend Corp. Historical chart here